Crystal structure of human serum albumin in complex with megabody reveals unique human and murine cross‐reactive binding site

Abstract excerpt

The pharmacokinetic properties of small biotherapeutics can be enhanced via conjugation to cross-reactive albumin-binding ligands in a process that improves their safety and accelerates testing through multiple pre-clinical animal models. In this context, the small and stable heavy-chain-only nanobody NbAlb1, capable of binding both human and murine albumin, has recently been successfully applied to improve the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Glycosylation and Glycoproteins Research
• Share to Monoclonal and Polyclonal Antibodies Research
• Share to Protein purification and stability